Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials

IMPORTANCE: Baricitinib, an oral selective Janus kinase inhibitor, improved the clinical signs and symptoms of moderate to severe atopic dermatitis in the 16-week, phase 3 monotherapy studies, BREEZE-AD1 and BREEZE-AD2. Long-term efficacy has not yet been examined. OBJECTIVE: To evaluate the long-te...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverberg, Jonathan I., Simpson, Eric L., Wollenberg, Andreas, Bissonnette, Robert, Kabashima, Kenji, DeLozier, Amy M., Sun, Luna, Cardillo, Tracy, Nunes, Fabio P., Reich, Kristian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117062/
https://www.ncbi.nlm.nih.gov/pubmed/33978711
http://dx.doi.org/10.1001/jamadermatol.2021.1273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117062/
https://www.ncbi.nlm.nih.gov/pubmed/33978711
http://dx.doi.org/10.1001/jamadermatol.2021.1273

Ejemplares similares